Medication Adherence Rating Scale (MARS)
Also known as: MARS
The Medication Adherence Rating Scale (MARS) is a 10-item self-report measure developed by Thompson, Kulkarni, and Sergejew in 2000 to assess medication adherence behaviors and attitudes in psychiatric populations, particularly antipsychotic medication use. Although originally validated in schizophrenia, it has been successfully applied across diverse medical conditions including hypertension, diabetes, and chronic disease management, providing a quick, sensitive assessment of actual adherence frequency and admission of problematic medication-taking behaviors.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The MARS is appropriate for any patient on long-term medication, with particular strength in psychiatric populations (antipsychotics, antidepressants, mood stabilizers) where insight and motivation vary substantially. It is valuable in clinical practice to identify non-adherers early and tailor interventions. It is also widely used in research as an adherence outcome measure in medication management trials and health services research. The brevity (10 items, 5 minutes) makes it suitable for busy clinical settings or large surveys.
Strengths & limitations
- Captures intentional non-adherence: Unlike refill counts or pill counts, directly assesses whether patients deliberately skip doses or reduce doses due to side effects or belief change.
- Clinically validated: Strong correlation with clinical outcomes (e.g., symptom relapse, hospitalization) in psychiatric and medical populations.
- Brief and practical: 10 items completed in ~5 minutes; feasible in routine clinical care.
- Validated across diverse conditions: Originally developed for antipsychotics but validated in asthma, diabetes, hypertension, cardiovascular disease, and other chronic conditions.
- Sensitive to behavior change: Changes in MARS scores correlate with intervention effects and clinical improvement.
- Self-report bias: Patients may underreport non-adherence due to social desirability or desire to please the clinician.
- Lack of objective validation: Cannot distinguish between accurate self-report and non-disclosure of non-adherence.
- Context-dependent thresholds: Optimal cutoff for 'good' vs. 'poor' adherence varies by disease and population; no universally accepted threshold.
- Limited detail on reasons: Does not systematically assess reasons for non-adherence (forgetfulness, side effects, cost, access, belief change); interview follow-up needed.
- Assumes stable medication regimen: May not accurately assess patients with recent dose changes or medication switches.
Frequently asked
What is the difference between MARS and pharmacy refill data?
Pharmacy refills show whether patients fill prescriptions (an objective, external measure) but not whether they actually take the medication. MARS asks patients directly about their actual medication-taking behavior. MARS captures intentional non-adherence (skipping doses due to side effects or belief change), which refills cannot detect. Both measures are valuable; together they provide a more complete picture.
Should I trust a patient's MARS score?
MARS is self-report, so it is vulnerable to social desirability bias. However, research shows that patients with good insight often provide honest MARS responses, especially in a non-judgmental clinical environment. Use MARS as a screening tool: high scores suggest good adherence, but low scores warrant exploration (open questions about barriers, direct observation if possible, serum drug levels if available). In psychiatric populations, poor insight may inflate MARS scores, so clinical correlation is essential.
Are there different MARS versions for different medications?
The original 10-item MARS is generic and applies to any medication. Some researchers have adapted it for specific conditions (e.g., MARS-5 for antipsychotics), but the 10-item version is the validated standard and is appropriate across conditions. Disease-specific adaptations are typically minor (e.g., replacing 'medication' with 'your blood pressure pills').
How does MARS relate to medication adherence interventions?
MARS is often used as an outcome measure to evaluate adherence interventions. Studies using MARS show that interventions addressing both belief barriers (e.g., psychoeducation) and practical barriers (e.g., simplified dosing, reminders) produce the largest increases in MARS scores and corresponding clinical improvement.
Sources
- Thompson, K., Kulkarni, J., & Sergejew, A. A. (2000). Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophrenia Research, 42(3), 241-247. DOI: 10.1016/s0920-9964(99)00130-9 ↗
How to cite this page
ScholarGate. (2026, June 3). Medication Adherence Rating Scale (MARS). ScholarGate. https://scholargate.app/en/pharmacology/medication-adherence-rating-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Beliefs about Medicines QuestionnairePharmacology↔ compare
- Drug Attitude InventoryPharmacology↔ compare
- Self-Efficacy for Appropriate Medication Use ScalePharmacology↔ compare
- Treatment Satisfaction Questionnaire for MedicationPharmacology↔ compare